Drug Trial Radar · NCT06128213
NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis
Last checked: Nov 19, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
13
Planned (sponsor's estimate)
Start
Mar 31, 2024
Primary completion
Jun 30, 2024
Study completion Sep 30, 2024
Sponsor
- Lead sponsor
- NeuroRx, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to test NRX101 in participants with complicated urinary tract infections including pyelonephritis. The main questions it aims to answer are: * Does NRX101 help participants resolve UTIs? * Is NRX101 safe for participants with UTIs? Participants will be seen in a doctor's office approximately 6 times to: * Answer a short 10 item questionnaire. * Review of side effects * Urine tests * Blood draw (about 10 ml or 2 teaspoons) * Review of medications * Review any signs or symptoms of UTI * Vital signs and weight (including blood pressure, heart rate, respiratory rate, and temperature) * Review of medical history This is an open-label study of NRX101, which means both you and your doctor know what drug you are taking. After the study is completed, researchers will look at the data to see if NRX101 helps participants with complicated UTI's.
Conditions
- Urinary Tract Infections
- Pyelonephritis
Interventions
NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone))Drug
oral NRX-101 (a fixed dose combination of 487.5 mg D-cycloserine (DCS) and 16.5 mg lurasidone HCl (lurasidone) twice daily for 10 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Microbiologic ResponseTime frame: Day 14
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.